lexington-massachusetts
(4)
CSA Medical, Inc.
CSA Medical is a Lexington, Massachusetts medical device company that develops spray cryotherapy technology for the lungs. Its flagship RejuvenAir System delivers a metered dose of -196°C liquid nitrogen through a bronchoscope to destroy the damaged, mucus-producing cells that drive chronic bronchitis in COPD patients, while preserving the underlying tissue matrix so healthy airway cells can regrow. Backed by roughly $161M in total funding including a $53M Series D in 2024, the company submitted its FDA PMA in January 2026 following a successful pivotal SPRAY-CB trial.
Wendelin Maners
Wendelin Maners is the President and CEO of CSA Medical, the Lexington, Massachusetts medical-device company behind the RejuvenAir System, a liquid-nitrogen cryospray technology delivered by bronchoscope. A finance-trained dealmaker who spent years buying and licensing emerging technologies for Boston Scientific, Maners moved from the deal table to the operating chair, taking the top job at CSA Medical in December 2019 and steering the company through an oversubscribed $53 million Series D and a fully enrolled pivotal trial on the road to FDA approval.
Hemanext
Hemanext is a Lexington, Massachusetts medical technology company that reengineers how donated red blood cells are stored. Its flagship system, Hemanext ONE, removes oxygen and carbon dioxide from red blood cell units during processing and keeps the environment hypoxic through 42 days of refrigerated storage, slowing the oxidative degradation known as the storage lesion. The system carries FDA marketing authorization (originally via the De Novo pathway) and a CE mark, and aims to deliver a higher-quality blood product for patients who depend on transfusion, including those with thalassemia, sickle cell disease, and trauma.
Martin Cannon
Martin Cannon is the founder and former president and CEO of Hemanext, the Lexington, Massachusetts company that turned an unproven idea - storing blood with the oxygen taken out - into an FDA-authorized, CE-marked medical device. Starting in the late 1990s with intellectual property licensed from Los Alamos National Laboratory and a handful of employees, he spent more than two decades building Hemanext into a recognized name in red blood cell transfusion, raising over $150 million in equity and NIH funding and securing more than 200 patents along the way. He retired in September 2023, handing the CEO role to longtime CTO Andrew Dunham, and now advises early-stage companies and mentors entrepreneurs.